Trademark: 85509412
Word
DIRECT TO PATIENT
Status
Dead
Status Code
606
Status Date
Monday, June 9, 2014
Serial Number
85509412
Mark Type
3000
Filing Date
Thursday, January 5, 2012
Published for Opposition
Tuesday, September 11, 2012
Abandoned Date
Monday, June 9, 2014

Trademark Owner History
Novartis AG - Owner At Publication

Classifications
35 Mail order and on-line retail pharmacy services; Retail specialized pharmacy services focusing on specific diseases, conditions and therapies, namely, serving groups of patients with common medical conditions and medication needs
Color is not claimed as a feature of the mark.
"DIRECT TO PATIENT"
The mark consists of a swoosh design over the words "DIRECT TO PATIENT".

Trademark Events
Jun 9, 2014
Abandonment Notice Mailed - No Use Statement Filed
Jun 9, 2014
Abandonment - No Use Statement Filed
Dec 12, 2013
Notice Of Approval Of Extension Request E-Mailed
Dec 11, 2013
Extension 2 Granted
Oct 29, 2013
Extension 2 Filed
Dec 7, 2013
Case Assigned To Intent To Use Paralegal
Oct 29, 2013
Teas Extension Received
May 7, 2013
Notice Of Approval Of Extension Request E-Mailed
May 3, 2013
Extension 1 Granted
May 3, 2013
Extension 1 Filed
May 3, 2013
Teas Extension Received
Nov 6, 2012
Noa E-Mailed - Sou Required From Applicant
Sep 11, 2012
Official Gazette Publication Confirmation E-Mailed
Sep 11, 2012
Published For Opposition
Aug 22, 2012
Notification Of Notice Of Publication E-Mailed
Aug 7, 2012
Law Office Publication Review Completed
Aug 7, 2012
Assigned To Lie
Jul 20, 2012
Approved For Pub - Principal Register
Jul 4, 2012
Teas/Email Correspondence Entered
Jul 3, 2012
Correspondence Received In Law Office
Jul 3, 2012
Teas Response To Office Action Received
Apr 5, 2012
Notification Of Non-Final Action E-Mailed
Apr 5, 2012
Non-Final Action E-Mailed
Apr 5, 2012
Non-Final Action Written
Mar 28, 2012
Assigned To Examiner
Jan 11, 2012
Notice Of Design Search Code Mailed
Jan 10, 2012
New Application Office Supplied Data Entered In Tram
Jan 9, 2012
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24